Hümmert, Martin W <br/><br/>
Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.  [electronic resource] 

 -  Multiple sclerosis and related disorders  May 2018 
 - 87-89 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>2211-0356 
<br/><br/><label>Standard No.: </label>10.1016/j.msard.2018.03.021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Alemtuzumab--therapeutic use<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Brain Stem--diagnostic imaging<br/>Daclizumab<br/>Drug Substitution<br/>Female<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Immunologic Factors--adverse effects<br/>Inflammation--etiology<br/>Multiple Sclerosis--diagnostic imaging<br/>Natalizumab--adverse effects